Scholar Rock

Scholar Rock. It is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics that selectively target the activation of growth factors in the TGFβ signaling pathway. Founded in 2012, the company leverages its proprietary platform to create highly specific inhibitors of cytokine and growth factor activation, with a particular emphasis on treating fibrosis, muscular atrophy, and anemia. Its lead programs are advancing through clinical trials for conditions including spinal muscular atrophy and cardiomyopathy related to transthyretin amyloidosis.

Company overview

Scholar Rock was founded in 2012 by scientific pioneers from the Whitehead Institute and MIT, including Professor Richard Hynes. The company is headquartered in the biotechnology hub of Cambridge, Massachusetts, and completed its initial public offering on the NASDAQ in 2018. Its scientific approach is built upon foundational research in extracellular matrix biology and latent TGFβ activation, aiming to intervene in disease processes at the point of growth factor activation rather than after signaling has been initiated. This strategy is designed to achieve greater selectivity and potentially improved therapeutic indices compared to traditional approaches targeting the TGFβ superfamily.

Research and development

The core of the company's research efforts is its proprietary platform for developing inhibitors of proprotein activation, which targets the precise molecular mechanisms that release active growth factors from their latent complexes. This platform has generated a pipeline of monoclonal antibody candidates designed to be highly selective for the active forms of targets like myostatin and TGFβ1. Key research areas include modulating muscle growth and function for disorders such as spinal muscular atrophy and countering fibrosis in organs including the heart and liver. The work is supported by ongoing research collaborations with academic institutions like Johns Hopkins University and has been recognized through awards from organizations such as the Muscular Dystrophy Association.

Clinical programs

The most advanced clinical program is apitegromab, a selective inhibitor of latent myostatin activation, which is being evaluated in the Phase 3 SAPPHIRE trial for patients with spinal muscular atrophy. Earlier phase trials, including the TOPAZ study, demonstrated promising results in improving motor function. Another key candidate is SRK-439, a myostatin inhibitor in preclinical development for obesity-related muscle loss. In the area of cardiology, the company is developing SRK-181, an inhibitor of latent TGFβ1 activation, which is being investigated in a Phase 1 trial for its potential to overcome resistance to anti-PD-1 therapy in solid tumors and has separate preclinical programs for cardiomyopathy associated with transthyretin amyloidosis.

Collaborations and partnerships

Scholar Rock has established several strategic alliances to advance its pipeline and platform. A significant global license and collaboration agreement with Gilead Sciences focuses on developing and commercializing inhibitors for fibrosis, including SRK-181, with potential milestone payments exceeding $1.5 billion. The company also maintains a research collaboration with Genentech, a member of the Roche Group, focused on discovering novel targets involved in TGFβ activation. These partnerships provide non-dilutive funding, access to complementary expertise in drug development and commercialization, and validate the potential of its targeted approach to growth factor biology.

Financials and corporate milestones

Following its initial public offering in 2018, the company has financed its operations through equity offerings, partnership milestones, and research funding. Major financial milestones include securing a $80 million private placement in 2020 and receiving substantial upfront payments from its collaboration with Gilead Sciences. Corporate milestones include the receipt of Fast Track designation and Orphan Drug designation from the U.S. Food and Drug Administration for apitegromab in spinal muscular atrophy, and the initiation of the pivotal Phase 3 SAPPHIRE trial. The company's financial strategy focuses on advancing its lead programs while leveraging partnerships to expand its research into new therapeutic areas like oncology and metabolic disease. Category:Biotechnology companies of the United States Category:Companies based in Cambridge, Massachusetts Category:Biopharmaceutical companies